Detailed Narrative
Strong Financial Performance in FY26
Thyrocare Technologies delivered robust financial results for Q4 and full-year FY26. Consolidated revenue grew 21% year-on-year to INR829 crores for FY26 and 20% to INR224 crores for Q4 FY26. Profit after tax (PAT) saw significant growth, increasing 81% year-on-year to INR163 crores for the full year, with Q4 PAT at INR48.7 crores, up 128% year-on-year. The company also reported a healthy EBITDA of INR262 crores for FY26, marking a 38% year-on-year increase.
Strategic Expansion into Specialty Diagnostics
The company is making a strategic foray into specialized diagnostics, including allergy testing, genomics, and histopathology, which is expected to be a major growth component in the next three years. While current capex for this expansion is modest at INR5-8 crores, the focus is on an opex-heavy model with a 40-person sales team and disruptive pricing. Management anticipates specialty services to eventually constitute 15-20% of its total mix within three years, aiming to democratize access to high-quality, affordable specialized tests.
Core Business Growth Drivers
Thyrocare's growth continues to be propelled by its franchisee and partnership businesses. The franchisee network reached a record 10,800 active franchisees in Q4 FY26, with additions expected to maintain a rate of 500 per quarter. The partnership business grew 32% year-on-year in FY26, although Q4 FY26 growth was 23% due to a high base from one-off📎 events in Q4 FY25. The company processed 210 million tests in FY26, a 23% increase, serving 19.2 million patients.
Focus on Quality and Efficiency
The company emphasized its commitment to high-quality diagnostics, evidenced by 97% of samples processed in NABL-accredited labs and a significant reduction in complaints to 3.06 per million tests in Q4 FY26. Operational efficiency was also a key focus, with the average turnaround time from sample receipt to report delivery improving to 3.43 hours in Q4 FY26. These efforts are aimed at strengthening patient and doctor trust and supporting scalable operations.
Margin Management and Capital Allocation
Gross margins improved to 74.7% in Q4 FY26, an increase of 113 basis points year-on-year, primarily due to better vendor negotiations and volume benefits. Management expects gross margins to stabilize in the 73-74% range and overall EBITDA margins (normalized 34% in FY26) to be maintained in FY27, with operating leverage reinvested into growth. The company maintains a strong balance sheet with over INR230 crores in net cash and zero debt as of March 31, 2026, and has recommended a final dividend of INR7 per equity share for FY26.
New Allied Business Venture
Thyrocare is planning to venture into an allied business of consumables and diagnostics, which management describes as a form of backward integration given the company's significant consumption of such items. Specific details regarding the segments and launch plan are expected to be disclosed by June or July, indicating a new strategic initiative to potentially diversify revenue streams and leverage existing scale.